Form 4: SOLENO CCO's Tax Withholding on RSU Vesting

Soleno Therapeutics' Chief Commercial Officer, Meredith Manning, reported a disposition of 1,922 common shares for tax obligations related to vested restricted stock units.

Summary

• Meredith Manning, Chief Commercial Officer of Soleno Therapeutics Inc. (SLNO), reported a transaction on December 15, 2025.
• The transaction involved the disposition of 1,922 shares of common stock at a price of $49.95 per share.
• These shares were withheld by the issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock units (RSUs) which vested on December 15, 2025.
• Following this transaction, Manning beneficially owns 43,429 shares, which include certain RSUs.

Sentiment

Score: 5

Explanation: Neutral. This is a routine, non-discretionary transaction for tax purposes related to RSU vesting, which is a standard part of executive compensation. It does not reflect a discretionary sale or purchase based on sentiment towards the company's prospects or operational performance.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance.

Industry Context

This is a routine insider transaction report detailing the tax withholding associated with the vesting of restricted stock units, a common form of executive compensation across various industries. It does not provide specific insights into broader industry trends or competitive dynamics.

Comparison to Industry Standards

• The practice of withholding shares to cover tax obligations upon RSU vesting is a standard and widely accepted compensation and tax management practice for executives across publicly traded companies, including those in the biotechnology and pharmaceutical sectors like Soleno Therapeutics.

Related Party Transactions

• The transaction involves the company withholding shares from its Chief Commercial Officer to cover tax obligations related to vested restricted stock units, which is a common form of related-party compensation transaction.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes related to executive compensation.
• Employees: Reflects standard executive compensation practices, where RSUs vest over time, aligning executive interests with long-term company performance.

Key Dates

Keywords

SOLENO THERAPEUTICS, SLNO, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Tax Withholding, Meredith Manning, Chief Commercial Officer